Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Spero Therapeutics (SPRO) Leases (2019 - 2025)

Spero Therapeutics (SPRO) has disclosed Leases for 7 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Leases fell 49.9% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2025, down 49.9%, and an annual FY2024 reading of $3.1 million, down 25.05% over the prior year.
  • Leases was $1.7 million for Q3 2025 at Spero Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Leases topped out at $6.9 million in Q1 2021 and bottomed at $1.7 million in Q3 2025.
  • Average Leases over 5 years is $4.6 million, with a median of $4.6 million recorded in 2023.
  • The sharpest move saw Leases skyrocketed 45.12% in 2021, then tumbled 49.9% in 2025.
  • Year by year, Leases stood at $6.5 million in 2021, then fell by 21.53% to $5.1 million in 2022, then decreased by 18.91% to $4.2 million in 2023, then dropped by 25.05% to $3.1 million in 2024, then tumbled by 45.6% to $1.7 million in 2025.
  • Business Quant data shows Leases for SPRO at $1.7 million in Q3 2025, $2.6 million in Q2 2025, and $2.8 million in Q1 2025.